| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
Celgosivir (MBI 3253; MDL 28574; MX3253) is a novel and potent α-glucosidase I inhibitor with the potential for the treatment of dengue fever. α-glucosidase is an enzyme that plays a critical role in viral maturation by initiating the processing of the N-linked oligosaccharides of viral envelope glycoproteins.
| ln Vitro |
In HIV-infected cells, celgosivir inhibits glycoprotein processing more effectively than the parent molecule (IC50=254 μM) to cause the buildup of glucosylated oligosaccharides. Celgosivir has an IC50 of 2.0±2.3 μM, indicating strong antiviral activity against HIV-1[1]. A closely related virus to the hepatitis C virus (HCV) is the bovine viral diarrhea virus (BVDV). In the plaque assay and cytopathic effect assay, celgosivir suppresses BVDV with IC50 values of 16 and 47 μM, respectively[2]. DENV2 replication is inhibited by celgosivir, with an EC50 of 0.2 μM. In relation to DENV1, 3, and 4, the EC50 values are less than 0.7 μM[3].
|
|---|---|
| ln Vivo |
At a dose of 50 mg/kg twice daily (BID) for five days, cegosivir completely protects AG129 mice against a deadly infection with a mouse-adapted dengue virus. It remains efficacious even after a 48-hour treatment delay. Celgosivir's protective effects vary depending on the dose and schedule; a 50, 25 or 10 mg/kg twice-day regimen is more effective than a 100 mg/kg dose taken once daily. Celgosivir quickly metabolizes to castanospermine, according to pharmacokinetic tests conducted in mice[4]. When mice were first infected with the mouse-adapted DENV strain S221, their viremia increased on day 3, but by day 10, 80% of them had recovered, and by day 8, the virus had totally disappeared[3].
|
| References |
|
| Additional Infomation |
Celgosivir is a 6-0-butanoyl ester derivative of castanospermine, a compound derived from the Australian chestnut with activity against hepatitis C virus. Celgosivir rapidly converts to castanospermine in the body, where it is a potent inhibitor of alpha-glucosidase I, a host enzyme required for viral assembly, release, and infectivity.
Drug Indication Investigated for use/treatment in hepatitis (viral, C). |
| Molecular Formula |
C12H21NO5
|
|---|---|
| Molecular Weight |
259.3
|
| Exact Mass |
259.141
|
| CAS # |
121104-96-9
|
| Related CAS # |
Celgosivir hydrochloride;141117-12-6
|
| PubChem CID |
60734
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
422.9±45.0 °C at 760 mmHg
|
| Flash Point |
209.6±28.7 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.569
|
| LogP |
-0.82
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
311
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O[C@@H]1[C@]2([H])[C@@H](O)[C@H](O)[C@@H](OC(CCC)=O)CN2CC1
|
| InChi Key |
HTJGLYIJVSDQAE-VWNXEWBOSA-N
|
| InChi Code |
InChI=1S/C12H21NO5/c1-2-3-9(15)18-8-6-13-5-4-7(14)10(13)12(17)11(8)16/h7-8,10-12,14,16-17H,2-6H2,1H3/t7-,8-,10+,11+,12+/m0/s1
|
| Chemical Name |
[(1S,6S,7S,8R,8aR)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate
|
| Synonyms |
MDL-28574 MBI-3253 60-P-001Celgosivir MBI3253 MDL28574 MX 3253
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8565 mL | 19.2827 mL | 38.5654 mL | |
| 5 mM | 0.7713 mL | 3.8565 mL | 7.7131 mL | |
| 10 mM | 0.3857 mL | 1.9283 mL | 3.8565 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
